-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Goli Pharmaceutical-B (01672.HK) announced that after receiving approval from the US Food and Drug Administration (FDA) New Drug Clinical Trial Application (IND), it has initiated two phase I studies to treat obesity in the US: a new generation pancreatic receptor agonist peptide ASC36 once a month to once a quarter, and ASC36 and GLP-1R/GIPR dual-target agonist polypeptide 35, the subcutaneous ASC36_35FDC monthly injection ASC36_35FDC.

Zhitongcaijing·08/10/2026 10:57:07
Listen to the news
Zhitong Financial App News, Goli Pharmaceutical-B (01672.HK) announced that after receiving approval from the US Food and Drug Administration (FDA) New Drug Clinical Trial Application (IND), it has initiated two phase I studies to treat obesity in the US: a new generation pancreatic receptor agonist peptide ASC36 once a month to once a quarter, and ASC36 and GLP-1R/GIPR dual-target agonist polypeptide 35, the subcutaneous ASC36_35FDC monthly injection ASC36_35FDC.